Surrozen, Inc./DE Payments to Acquire Productive Assets
Surrozen, Inc./DE (SRZN) reported Payments to Acquire Productive Assets of $280.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2026-03-23
- Surrozen, Inc./DE payments to acquire productive assets for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE payments to acquire productive assets for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE payments to acquire productive assets for the quarter ending 2023-03-31 was $85.00K.
- Surrozen, Inc./DE payments to acquire productive assets for the quarter ending 2022-12-31 was $76.00K.
- Surrozen, Inc./DE payments to acquire productive assets for fiscal 2025 was $280.00K, a 3011.11% increase from fiscal 2024.
- Surrozen, Inc./DE payments to acquire productive assets for fiscal 2024 was $9.00K.
- Surrozen, Inc./DE payments to acquire productive assets for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Surrozen, Inc./DE payments to acquire productive assets for fiscal 2022 was $85.00K, a 286.36% increase from fiscal 2021.
| Period end | Payments to Acquire Productive Assets 3 month | Payments to Acquire Productive Assets 6 month | Payments to Acquire Productive Assets 9 month | Payments to Acquire Productive Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $280.00K 10-K · filed 2026-03-23 | |||
| 2024-12-31 | $9.00K 10-K · filed 2026-03-23 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 | |||
| 2023-03-31 | $85.00K 10-Q · filed 2024-05-08 | $161.00K derived: sum of 2 quarters · filed 2024-05-08 | $170.00K derived: sum of 3 quarters · filed 2024-05-08 | $170.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | $85.00K derived: sum of 2 quarters · filed 2024-04-10 | $85.00K derived: sum of 3 quarters · filed 2024-04-10 | $85.00K 10-K · filed 2024-04-10 |
| 2022-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $9.00K derived: sum of 2 quarters · filed 2023-11-08 | $9.00K 10-Q · filed 2023-11-08 | -$177.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | -$186.00K derived: sum of 3 quarters · filed 2023-05-10 | -$134.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | -$186.00K derived: sum of 2 quarters · filed 2023-05-10 | -$134.00K derived: sum of 3 quarters · filed 2023-05-10 | -$15.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$186.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$134.00K derived: sum of 2 quarters · filed 2023-03-31 | -$15.00K derived: sum of 3 quarters · filed 2023-03-31 | $22.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $171.00K derived: sum of 2 quarters · filed 2022-11-14 | $208.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $156.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $37.00K 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $267.00K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |